GLP-1s and Midlife Metabolism: Dr. Rocio Salas-Whalen Breaks Down the Science of Weight Loss and Menopause: Part 1

unPAUSED with Dr. Mary Claire Haver

Mary Claire Media, LLC

Medicine, Health & Fitness, Society & Culture

4.8 • 1.2K Ratings

🗓️ 11 November 2025

⏱️ 60 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

Are GLP-1 medications a game-changer for women in midlife—or just another quick fix? In this conversation, triple Board-certified in Obesity Medicine; fellowship-trained in Endocrinology, Diabetes & Metabolism Dr. Rocio Salas-Whalen joins Dr. Mary Claire Haver to cut through the hype and share what women really need to know about Ozempic, Wegovy, Mounjaro, and the science behind sustainable weight loss. Dr. Salas-Whalen, founder of New York Endocrinology and author of the upcoming book Weightless, explains why GLP-1 receptor agonists represent a fundamental shift in how we understand and treat obesity—not as a willpower problem, but as a chronic medical condition with biological drivers including hormones, genetics, and metabolism. For women navigating perimenopause and menopause, the conversation gets even more specific. Dr. Salas-Whalen breaks down why estrogen decline drives fat redistribution to the abdomen, increases visceral fat, and makes it nearly impossible to lose weight using the same strategies that worked before. She reveals how GLP-1 medications can address the metabolic changes of midlife while protecting what matters most: muscle mass. Dr. Salas-Whalen shares her clinical experience treating thousands of patients and addresses the viral misinformation circulating online. She explains why obesity is a transgenerational disease influenced by genetics, environment, food accessibility, and even childhood trauma—not personal failure. Guest links: Meet Your Endocrinologist - Dr. Salas-Whalen (NY Endocrinology) Dr. Rocio Salas-Whalen (Instagram) Books “Weightless: A Doctor's Guide to GLP-1 Medications, Sustainable Weight Loss, and the Health You Deserve” by Dr. Rocio Salas-Whalen “The New Perimenopause,”⁠ by Dr. Mary Claire Haver ⁠"The New Menopause"⁠ by Dr. Mary Claire Haver Articles Loss of Visceral Fat is Associated with a Reduction in Inflammatory Status in Patients with Metabolic Syndrome (Molecular Nutrition and Food Research) Increased visceral fat and decreased energy expenditure during the menopausal transition (International Journal of Obesity) Sex-specific body fat distribution predicts cardiovascular ageing (European Heart Journal) Association between metabolic healthy obesity and female infertility: the national health and nutrition examination survey, 2013–2020 (BMC Public Health) The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity (PNAS) Skeletal Muscle as Endocrine Organ (Advances in Experimental Medicine and Biology) Preserving Healthy Muscle during Weight Loss (Advances in Nutrition) 32nd European Congress on Obesity (ECO 2025) (S. Karger AG, Basel) Association of Obesity With COVID-19 Severity and Mortality: An Updated Systemic Review, Meta-Analysis, and Meta-Regression (Frontiers in Endocrinology) Adverse Events Related to Tirzepatide (Journal of the Endocrine Society) Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use (Menopause) Clinical development times for innovative drugs (Nature Reviews Drug Discovery) The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect (Cardiovascular Diabetology) Dose-dependent pancreatitis risk associated with GLP-1 agonists (Journal of Diabetes and Metabolic Disorders) Mortality from type 2 diabetes mellitus across municipalities in Mexico (Arch Public Health) The association between age of menopause and type 2 diabetes: a systematic review and meta-analysis (Nutrition & Metabolism) Obesity in Infertile Women, a Cross-Sectional Study of the United States Using NSFG 2011-2019 (Reproductive Sciences) Bisphenol A and the Risk of Obesity a Systematic Review With Meta-Analysis of the Epidemiological Evidence (Dose-Response) For full show notes, please click here. To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	You've heard of osempic face, but have you heard of osempic liver and showing an improvement in the liver function test or the osempic pancreas, less insulin resistance, right?
0:09.7	Because there's more good than bad with these medications.
0:13.7	And whenever a drug is FDA approved or whenever I prescribe a drug, it's because I know the benefits await the risks.
0:20.1	If it's on the right hands, we're going to have very minimal side effects.
0:24.1	Okay.
0:24.6	If it's in the wrong hands, somebody who doesn't know how this drug work, they don't know
0:28.5	how to guide the patient, right?
0:30.8	Then that's where we see this crazy side effects that we're hearing in the headlines.
0:44.4	Okay. crazy side effects that we're hearing in the headlines. The views and opinions expressed on unpause are those of the talent and guests alone.
0:49.2	They are provided for informational and entertainment purposes only.
0:52.6	No part of this podcast or any related
0:54.5	materials are intended to be a substitute for professional medical advice,
0:58.1	diagnosis, or treatment. Menopause weight gain is so incredibly common. 80% of my
1:05.6	patients come in with unexplained body composition changes as they're going
1:09.7	through perimenopause and menopause.
1:12.2	It can be so difficult to lose that weight and keep it off with diet and exercise alone.
1:18.5	Quite frankly, when I first heard the hype around GLP-1s, I was skeptical.
1:23.7	Everything I saw on social media described it as the easy way out and that it was cheating.
1:28.7	I hadn't realized that GLP1 medications had been used safely in diabetes care for more than 20 years
1:35.1	before they suddenly became part of the public conversation around weight and metabolic health.
1:40.6	Then I came across our guest, Dr. Rosio Salasuelan, on social media, and she explained
1:46.3	these medications in such a compassionate, clear, and evidence-based way that I learned more in
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Mary Claire Media, LLC, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Mary Claire Media, LLC and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.